Highlights
About
Innovative Treatments for Patients with Fibro-Inflammatory-Related Diseases
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class monoclonal antibody designed to neutralize CCL24 activity.
In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from a Phase 2 liver fibrosis biomarker study in NASH patients and an investigator study in patients with severe lung injury.
A global Phase 2 trial in primary sclerosing cholangitis patients is ongoing, with a top-line data readout targeted for the second half of 2024.
Identity
| Name | Chemomab Therapeutics |
|---|---|
| Slug | chemomab |
| Type / kind | startup |
| Crunchbase ID | chemomab |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoMrEoLkKDA |
Status
| Status | active |
|---|---|
| Status reason | Public on NASDAQ on Mar, 2021<br> |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | Kiryat Atidim, Tel Aviv-Yafo, Israel |
Web & social
| Website | https://chemomab.com |
|---|---|
| https://www.linkedin.com/company/18948873 |
Classifications
Funding
| Total raised | $90.5M |
|---|---|
| Current stage | Public |
| Market cap | $10.2M |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}